NL-OMON50370已完成不适用
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors - ELE18421-184021 (XL184-021)
Exelixis, Inc0 个研究点目标入组 25 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •see protocol (enclosed to submission)
排除标准
- •see protocol (enclosed to submission)
研究者
相似试验
进行中（未招募）
1 期
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsUrothelial CarcinomaCastration-resistant Prostate CancerTriple Negative Breast CancerEndometrial CancerGastroesophageal Junction AdenocarcinomaColorectal CancerOvarian CancerGastric CancerHead and Neck CancerDifferentiated Thyroid CancerLower Esophageal CancerRenal Cell CarcinomaHepatocellular CarcinomaNon-Small Cell Lung CancerNCT03170960Exelixis914
已完成
1 期
METBEIGE Studycolorectal cancerJPRN-jRCT2080224606ational Cancer Center Hospital East54
进行中（未招募）
1 期
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.CTIS2024-511292-15-00Grupo Espanol De Tumores Neuroendocrinos41
招募中
1 期
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerNCT05613894University of Utah33
进行中（未招募）
1 期
A Phase I study of cabozantinib monotherapy in pediatric patients with recurrent and/or refractory solid tumorsRefractory pediatric solid tumorMalignant solid tumorsD009369JPRN-jRCT2031210610Arakawa Ayumu18